ESC 365 - Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

Back

ESC Professional Premium Access

Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

Session: Diabetes and stable coronary artery disease

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor V. Ritsinger (Stockholm, SE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Viveca Ritsinger

Karolinska Institute, Stockholm (Sweden)

0 follower

6 more presentations in this session

Does prediabetes diagnosed by hemoglobinA1c or oral glucose tolerance test predict coronary artery disease in patients suspected of chronic coronary syndrome?

Speaker: Doctor K. Overgaard (Svendborg, DK)

Vessel-oriented cardiovascular events in patients with diabetes undergoing intracoronary physiology-guided revascularization

Speaker: Doctor S. Sgreva (Verona, IT)

Synergistic adverse impact of diabetes and chronic kidney disease on cardiovascular mortality in patients underwent percutaneous coronary intervention

Speaker: Doctor S. Moriya (Tokyo, JP)

Diabetes mellitus and response to IL-1 blockade with Anakinra after ST-elevation myocardial infarction: a pooled analysis of the VCU-ART studies

Speaker: Doctor F. Moroni (Charlottesville, US) Doctor A. Abbate (Charlottesville, US)

Impact of diabetes status and chronic kidney disease on myocardial infarction mortality among elderly patients - a retrospective analysis of data from an ongoing nationwide registry.

Speaker: Doctor P. Asser (Tartu, EE)

Access the full session

Diabetes and stable coronary artery disease

Speakers: Doctor V. Ritsinger, Doctor K. Overgaard, Doctor S. Sgreva, Doctor S. Moriya, Doctor F. Moroni...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

About the speaker

Doctor Viveca Ritsinger

6 more presentations in this session

Does prediabetes diagnosed by hemoglobinA1c or oral glucose tolerance test predict coronary artery disease in patients suspected of chronic coronary syndrome?

Vessel-oriented cardiovascular events in patients with diabetes undergoing intracoronary physiology-guided revascularization

Synergistic adverse impact of diabetes and chronic kidney disease on cardiovascular mortality in patients underwent percutaneous coronary intervention

Diabetes mellitus and response to IL-1 blockade with Anakinra after ST-elevation myocardial infarction: a pooled analysis of the VCU-ART studies

Impact of diabetes status and chronic kidney disease on myocardial infarction mortality among elderly patients - a retrospective analysis of data from an ongoing nationwide registry.

Access the full session

Diabetes and stable coronary artery disease

About the event

ESC Congress 2023

ESC 365 is supported by